Methodological guideline for REA of pharmaceuticals: Safety
This guideline aims at providing a framework for the evaluation of relative safety performed by HTA assessors in the context of Relative Effectiveness Assessment (REA) of pharmaceuticals. When performing relative safety assessment the safety profile of the pharmaceutical is assessed in comparison to the comparator(s) of the same or different therapeutic class and to the […]
Methodological guideline for REA of pharmaceuticals: Surrogate endpoints
This guideline provides a set of recommendations for the selection and assessment of surrogate endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. Surrogate endpoints act as substitutes for clinical endpoints and are expected to predict the effect of therapy (benefit and/or harm). An improvement in surrogate endpoint may be or may not be […]
Methodological guideline for REA of pharmaceuticals: Clinical endpoints
This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. Clinical endpoints are regarded as a means to measure the impact of a treatment on how a patient feels, functions and survives. That impact is usually in the form of improved […]
A new application of the HTA Core Model – the HTA Core Model for Rapid Relative Effectiveness Assessment of pharmaceuticals
The HTA Core Model defines the content elements to be considered in a health technology assessment (HTA) and facilitates standardised reporting. The aim is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-production of HTA reports (by multiple HTA agencies). Detailed information […]
Public consultation on HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals
This document presents the public consultation of WP5 HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals. The draft HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceutical under production by Work Package 5 Joint Action 1 was open for public consultation from 1 October 2012 to 30 November 2012. Objectice of the […]
A new application of the HTA Core Model – the HTA Core Model for Rapid Relative Effectiveness Assessment of pharmaceuticals
The HTA Core Model defines the content elements to be considered in a health technology assessment (HTA) and facilitates standardised reporting. The aim is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-production of HTA reports (by multiple HTA agencies). Detailed information […]
List of commentators for the WP5 JA1 Pilot Pazopanib Report
The list with commentators provides the contact information of all the organisations that properly submitted contributions. The list with commentators provides the contact information of all the organisations that properly submitted contributions. List of commentators for the WP5 JA1 Pilot Pazopanib Report
List of comments for the WP5 JA1 Pilot Pazopanib Report
The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. The list of comments for the WP5 JA1 Pilot Pazopanib Report. The list provides the contact information of all the organisations that properly submitted their contributions. This document is […]
WP5 JA1 Pilot Pazopanib Report+Appendix
The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The final version of the WP5 […]
WP5 JA1 Pilot Pazopanib Report+Appendix
WP5 JA1 Pilot Pazopanib Report+Appendix The final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals and guidelines. The joint assessment involved the participation of 22 HTA organisations as authors on different domains or as reviewers. Find the full list on page 16 in side the report. The […]
